Elagolix

Elagolix is a small-molecule, orally available GnRH receptor antagonist developed by AbbVie together with Neurocrine Biosciences. Unlike the older injectable GnRH agonists, which first stimulate and then desensitize the pituitary, elagolix blocks the GnRH receptor directly and produces a rapid, dose-dependent, and reversible fall in the pituitary hormones that drive the ovaries ^[1]. Chemically it is a fluorinated, pyrimidine-based compound.

Its first approved use, granted in the United States in 2018, is for the management of moderate to severe pain associated with endometriosis, an estrogen-dependent condition. Two large phase 3 trials (Elaris EM-I and EM-II) showed that elagolix reduced menstrual pain and non-menstrual pelvic pain compared with placebo, with the higher dose giving greater relief; extension studies confirmed that these benefits were sustained over a full year of treatment ^[1][2].

Elagolix is also used, in a fixed combination with low-dose estradiol and norethindrone acetate (an approach called add-back therapy), to treat heavy menstrual bleeding from uterine fibroids. In phase 3 trials, elagolix with add-back therapy markedly reduced menstrual blood loss compared with placebo, while the added hormones offset some of the bone-density loss and hot flushes caused by low estrogen ^[3].

Because elagolix lowers estrogen, its characteristic side effects are hypoestrogenic ones: hot flushes, reduced bone mineral density, and changes in blood lipids, which limit how long it can be taken without add-back therapy ^[1][3]. It is available as oral tablets, sold as Orilissa for endometriosis and as a co-packaged product with estradiol and norethindrone under the name Oriahnn for fibroids.

Elagolix is a prescription hormone-blocking pill, and its side effects come from lowering estrogen. Expect menopause-like symptoms such as hot flashes, night sweats, headache, and mood changes, along with lighter periods or none at all. The big concern with longer use is bone thinning, so treatment length is capped and calcium and vitamin D are encouraged; the fibroid version adds hormonal add-back partly to protect bone. It can raise liver enzymes and is avoided in severe liver disease and osteoporosis. Because it can allow pregnancy early in a cycle yet is unsafe in pregnancy, non-hormonal contraception is advised.

Elagolix is a weak inhibitor of the hepatic enzyme CYP2C19. When elagolix 300 mg is given twice daily, it increases exposure of the CYP2C19 substrate omeprazole by 1.8-fold overall, with 2-2.5-fold increases in CYP2C19 extensive and intermediate metabolizers and a 40% decrease in poor metabolizers, a pharmacokinetic interaction where elagolix changes omeprazole metabolism ^[6].

Elagolix also inhibits the intestinal uptake transporter OATP2B1; this inhibition causes reductions in the bioavailability of OATP2B1 substrates like rosuvastatin, with AUC decreases of 40-50%, a distinct pharmacokinetic mechanism from CYP inhibition ^[7]. CYP2C19 substrate medications may require dosage adjustment when initiated with elagolix. Interactions not comprehensively documented include effects on other CYP enzyme systems at clinically relevant doses, long-term effects with extended elagolix therapy, and multi-drug interactions in patients taking multiple CYP2C19 or OATP2B1 substrates simultaneously.

Checking a whole stack? Run it through interactions + stacks.

Elagolix was discovered by Neurocrine Biosciences as part of a search for orally active, non-peptide antagonists of the gonadotropin-releasing hormone (GnRH) receptor, and it was subsequently developed in partnership with AbbVie. Its defining innovation was that, unlike the injectable GnRH agonists that had long been used to suppress reproductive hormones, elagolix could be taken as a tablet and produced a rapid, dose-dependent, and readily reversible reduction in estrogen without the initial hormone surge, or flare, characteristic of the older agents.

This dose-tunable suppression allowed lower doses for pain and higher doses, combined with hormonal add-back, for heavy bleeding. In July 2018 the United States Food and Drug Administration approved it under the brand name Orilissa for moderate to severe pain associated with endometriosis, making it the first oral GnRH antagonist cleared for the condition. A combination product adding hormonal add-back therapy was later approved for heavy menstrual bleeding due to uterine fibroids. The pivotal endometriosis trials were reported by Taylor and colleagues in the New England Journal of Medicine in 2017.

Elagolix is valued as a meaningful advance for women with endometriosis, offering an oral, flexible, and quickly reversible way to lower estrogen and reduce the disease's often debilitating pelvic pain and painful periods. Its dose-adjustable design lets treatment be tailored to the severity of symptoms, and the avoidance of the hormonal flare seen with older GnRH agonists is a practical benefit at the start of therapy.

Randomized trials have documented significant improvements in both menstrual and non-menstrual pelvic pain. The candid trade-off is that lowering estrogen produces menopause-like effects such as hot flashes and, importantly, a reduction in bone mineral density that limits how long the higher doses can be used without add-back therapy. Prescribed thoughtfully and with appropriate monitoring, it represents a genuinely useful, patient-friendly option in a field where effective oral treatments have historically been scarce.